Moreover, to confirm the CB2 anti-inflammatory properties in ITP-MSCs, we blocked CB2 with the reverse agonist AM630 (1 μM) that respectively increased and decreased IL-6 and IL-4 release, and significantly counteracted the effects induced by JWH-133. Here, IL4 is linked to autoimmune thrombocytopenic purpura.